More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.

Original title: “Novo may have muscle advantage over Lilly in weight-loss race: preprint”

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.

Original title: “Kailera nets $625M in one of biotech’s biggest-ever IPOs”

The findings, which come amid FDA scrutiny of Foundayo’s safety, will enable Lilly to seek a new clearance in diabetes.

Original title: “Lilly’s new obesity pill passes heart safety test in diabetes”

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the indication.

Original title: “Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns”

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.

Original title: “FDA asks Lilly to evaluate obesity pill’s liver risk”

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

Original title: “Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data”

approved weight loss drugs for obesity with a thorough emphasis on glp 1 agonist medications a systematic review

Original title: “Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.”

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.

Original title: “Lilly investing billions to prepare for overseas oral GLP-1 launches”

Two health-care companies began formally marketing US initial public offerings raising as much as $693 million in aggregate, as listing activity in the once-prolific sector increases. Obesity biotech Kailera Therapeutics Inc. revealed it is seeking to raise as much as $533 million from an IPO to help fund the development of its pipeline of obesity drugs.

Original title: “Life Science Firms Seek $693 Million in US IPOs as Pace Picks Up - Bloomberg”

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has come from behind the Danish rival in the weight loss space before, last time it clearly had the better drug.

Original title: “With oral obesity race underway, all eyes are on Lilly’s Foundayo launch”

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

Original title: “Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk”

Novo escalated a GLP-1 pricing war with the launch of its newest obesity medicine. Elsewhere, analysts came to Insmed’s defense and HHS changed the way panelists for a key vaccine committee are selected.

Original title: “Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure”

The approval of Eli Lilly’s oral obesity drug officially ignites an intense competition with Novo Nordisk’s oral Wegovy; Gilead Sciences and Neurocrine Biosciences keep the M&A train chugging; Trump hits pharma with his long promised tariffs, and the FDA proposes many changes with 2027 budget.

Original title: “Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma”

After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since January.

Original title: “Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences”

pharmacological management of obesity in prader willi syndrome what does the future hold

Original title: “The pharmacological management of obesity in Prader-Willi syndrome: what does the future hold?”

Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.

Original title: “FDA approves Lilly obesity pill, triggering battle with Novo Nordisk”

The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.

Original title: “Eli Lilly's Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry”

The $100 million Series B round will be used to bring the biotech’s oral GLP-1 into early human testing.

Original title: “Ambrosia adds a megaround for obesity drugs”

tirzepatide in metabolic diseases clinical efficacy and safety beyond diabetes and obesity

Original title: “Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity.”

The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s now in late-stage testing.

Original title: “Obesity drugmaker Kailera plans an IPO”